Glucose Health, Inc. –
Amazon Revenues Exceed
$50,000 Per Month
BENTONVILLE, AR --
March 1, 2021 -- InvestorsHub NewsWire -- GLUCODOWN®
revenues
at Amazon for the month of February 2021 were $52,419
–
a 362%
increase compared to February 2020 revenues of
$11,349. Sequentially,
February 2021 revenues
of
$52,419 at Amazon,
exceeded
January
2021 revenues
of
$34,551, a 51%
increase. Importantly,
during
February
2021
most
GLUCODOWN®
listings
at Amazon were in-stock
and
available for purchase.
For
further comparison, Glucose Health,
Inc.'s total
Q1
fiscal
2020
revenues (from
all
retailer partners including Walmart) were
$82,613.
For
just the first two months
of
Q1 fiscal
2021, Amazon revenues
alone, were
$86,890.
Glucose
Health, Inc. (OTC:
GLUC) will release its
fiscal 2020 annual report and first quarter 2021 revenue
update, Wednesday March 31,
2021.
CEO
Murray Fleming stated: "GLUCODOWN®
is
an
entirely
original product
– no
other beverage company, multinational or
start-up, past or
present, has ever conceived
of
taking a ubiquitous soft drink, iced tea,
and painstakingly re-formulating it into the
perfect beverage choice
for upwards of
100
million persons – America's
growing population of diabetics and
pre-diabetics. While
GLUCODOWN®'s
revenue
growth trajectory
is
impressive, the fact is our brand
is only in
the
very
earliest
stages of being discovered by this massive
consumer segment."
About Glucose Health, Inc. (OTC: GLUC)
More than
100 million Americans are estimated to be diabetic or pre-diabetic,
by the Centers for Disease Control and
Prevention.2
Introduced
in
2018 and manufactured by
Glucose Health, Inc., the
GLUCODOWN®
brand
has
come
to define an entirely
new and distinct dietary supplement
category – functional,
diabetic
friendly,
beverages. By specializing in
producing delicious and
efficacious beverages
nutritionally appropriate1
for the
nation's 100+ million pre and Type-2 diabetics, GLUCODOWN® is
uniquely and strongly positioned among all up & coming beverage
companies in America. Glucose Health, Inc.
is a publicly traded company with the ticker symbol OTC:
GLUC.
For more GLUC news
visit www.glucosehealthinc.com
Like us on Facebook at www.facebook.com/glucodown
1
For
citations visit www.glucodown.com/clinical-data
2
National Diabetes Statistics Review, 2020;
Centers for Disease Control and Prevention, Department of Health
and Human Services.
This
news
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and
while
Glucose
Health, Inc. is not subject to the 1934 Securities and Exchange
Act, contains
forward-looking statements within the meaning Section 21E of the
Securities and Exchange Act of 1934, as amended. Statements that
are not a description of historical facts constitute
forward-looking statements and may often, but not always, be
identified by the use of such words as "expects,"
"anticipates," "intends,"
"estimates," "plans," "potential, "possible," "probable,
"believes," "seeks," "may, "will, "should," "could" or the negative
of such terms or other similar expressions. Actual results may
differ materially from those set forth in this release due to the
risks and uncertainties inherent in the Company's business. Readers
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement and the Company undertakes no obligation to
revise or update this release to reflect events or circumstances
after the date hereof.
Contact:
Murray
Fleming
Glucose Health,
Inc.
info@glucosehealthinc.com
(479)
802-3827
